Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INSM
CUSIPN/A
Phone908-977-9900
Debt
Debt-to-Equity Ratio0.70
Current Ratio20.01
Quick Ratio20.01
Price-To-Earnings
Trailing P/E Ratio-9.21
Forward P/E Ratio-6.41
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$4.71 per share
Price / Book5.65
Profitability
EPS (Most Recent Fiscal Year)($2.89)
Net Income$-192,640,000.00
Net MarginsN/A
Return on Equity-68.14%
Return on Assets-46.47%
Miscellaneous
Employees214
Outstanding Shares76,620,000
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.89) EPS for the quarter, topping analysts' consensus estimates of ($0.96) by $0.07. View Insmed's Earnings History.
What price target have analysts set for INSM?
8 brokers have issued twelve-month price targets for Insmed's stock. Their predictions range from $31.00 to $54.00. On average, they expect Insmed's stock price to reach $40.00 in the next twelve months. View Analyst Ratings for Insmed.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Alkermes (ALKS), SAGE Therapeutics (SAGE), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Loxo Oncology (LOXO), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), FibroGen (FGEN), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Madrigal Pharmaceuticals (MDGL) and Ultragenyx Pharmaceutical (RARE).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis, Pres, CEO & Director (Age 49)
- Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)
- Ms. S. Nicole Schaeffer, Chief People Strategy Officer (Age 50)
- Dr. Eugene J. Sullivan M.D., FCCP, Chief Product Strategy Officer (Age 53)
- Mr. Andrew T. Drechsler, Advisor (Age 46)
Has Insmed been receiving favorable news coverage?
Headlines about INSM stock have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a news impact score of 0.13 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 46.20 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Insmed's major shareholders?
Insmed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (9.34%), Redmile Group LLC (2.83%), Foresite Capital Management II LLC (1.26%), Northern Trust Corp (1.25%), Nexthera Capital LP (1.20%) and Lord Abbett & CO. LLC (1.04%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed.
Which institutional investors are selling Insmed stock?
INSM stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, C WorldWide Group Holding A S, Victory Capital Management Inc., Teacher Retirement System of Texas, Sei Investments Co., Legal & General Group Plc, California State Teachers Retirement System and American International Group Inc.. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr, Melvin Md Sharoky and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Which institutional investors are buying Insmed stock?
INSM stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Foresite Capital Management II LLC, Nexthera Capital LP, Bellevue Group AG, Summit Trail Advisors LLC, PointState Capital LP, Lord Abbett & CO. LLC and California Public Employees Retirement System. View Insider Buying and Selling for Insmed.
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $26.62.
How big of a company is Insmed?
Insmed has a market capitalization of $2.05 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
